Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 10, 2012, Pages 2537-2543

  Maki, N ^a   Ohkuchi, A ^b   Tashiro, Y ^a   Kim, M R ^c   Le, M ^c   Sakamoto, T ^a   Matsubara, S ^b   Hakamata, Y ^a  

^a SHIZUOKA GENERAL HOSPITAL   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; IMMUNOSUPPRESSIVE AGENT; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; HUMAN; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; BODY WEIGHT; CREATININE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TERTIARY CARE CENTERS; VANCOMYCIN; YOUNG ADULT;

EID: 84869100719     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1593-y     Document Type: Article

References (17)

1. Geraci JE (1977) Vancomycin. Mayo Clin Proc 52:631-634
2. Cook FV, Farrar WE Jr (1978) Vancomycin revisited. Ann Intern Med 88:813-818
3. Bailie GR, Neal D (1988) Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 3:376-386
4. Geraci JE, Heilman FR, Nichols DR, Wellman EW, Ross GT (1956) Some laboratory and clinical experiences with a new antibiotic, vancomycin. In: Welch H, Marti-Ibanez F (eds) Antibiotics annual 1956-1957. Medical Encyclopedia Inc., New York, pp 90-106
5. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
6. Llopis-Salvia P, Jiménez-Torres NV (2006) Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 31:447-454
7. Moellering RC Jr, Krogstad DJ, Greenblatt DJ (1981) Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94:343-346
8. Matzke GR, McGory RW, Halstenson CE, Keane WF (1984) Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433-437
9. Maeda Y, Omoda K, Fukuhara S, Ohta M, Ishii Y, Murakami T (2006) Evaluation of clinical efficacy of Maeda's nomogram for vancomycin dosage adjustment in adult Japanese MRSA pneumonia patients. Drug Metab Pharmacokinet 21:54-60
10. Lake KD, Peterson CD (1985) A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 5:340-344
11. Pryka RD, Rodvold KA, Erdman SM (1991) An updated comparison of drug dosing methods. Part IV: vancomycin. Clin Pharmacokinet 20:463-476
12. Cohen E, Dadashev A, Drucker M, Samra Z, Rubinstein E, Garty M (2002) Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 49:155-160
13. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of theAmerican Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98. doi:10.2146/ajhp080434
14. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G (2007) Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51:1089-1091
15. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS (2003) Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187:929-938
16. Murphy JE, Gillespie DE, Bateman CV (2006) Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 63:2365-2370
17. Tajiri C, Yuasa S, Kabeya M, Aoki Y, Kawai M, Kusafuka H (2009) Comparison of predictive formulas of renal function for initial dose regimen of vancomycin hydrochloride: Cockcroft & Gault, Horio and Japanese Estimated GFR Formulas. Jpn J Ther Drug Monit 26:103-110 (in Japanese, abstract in English)